Please assess the completion status of the following clinical trial:

Trial Title: ADASUVE 2-dose Thorough QT/QTc Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between the ages of 18 to 65 years, inclusive.~* Body mass index (BMI) ≥18 and ≤32.~* Subjects who are willing and able to comply with the study schedule and requirements, and stay at the CRU for a 4-day period and 2 consecutive 3-day periods.~* Subjects who speak, read, and understand English and/or Dutch and are willing and able to provide written informed consent on an IEC approved form prior to the initiation of any study procedures.~* Subjects who are in good general health prior to study participation~* Female or male participants who agree to use a medically acceptable and effective birth control method~Exclusion Criteria:~* Subjects who regularly consume large amounts of xanthine-containing substances (≥ 5 cups of coffee/day).~* Subjects who have taken prescription or nonprescription medication within 5 days of Visit 2.~* Subjects who have had an acute illness within the last 5 days of Visit 2.~* Subjects who have smoked tobacco within the last 30 days or who have a positive cotinine test.~* Subjects who have a history of HIV, anti-HCV or HbsAg positivity.~* Subjects who have a history within the past 2 years of drug or alcohol dependence or abuse as defined by DSM-IV.~* Subjects who test positive for alcohol or have a positive urine drug screen.~* Subjects who have a history of allergy or intolerance to loxapine or amoxapine or history of bronchospasm following inhaled loxapine treatment.~* Subjects who have an ECG abnormality.~* Subjects who have hypotension, or hypertension.~* Subjects who have a history of unstable angina, syncope, coronary artery disease, myocardial infarction, congestive heart failure, transient ischemic attack, history of convulsions or other neurological disorder.~* Subjects who have a current history of asthma, chronic obstructive lung disease, or any other lung disease associated with bronchospasm.~* Subjects who use medications to treat airways disease, such as asthma or COPD.~* Subjects who have any acute respiratory signs/symptoms (e.g., wheezing).~* Female subjects who have a positive pregnancy test at screening or at admission to any of the treatment visits, or are breastfeeding.~* Subjects who have received an investigational drug within 60 days prior to the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment sequence ABC (Type: OTHER): Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
- Treatment sequence ACB (Type: OTHER): Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
- Treatment sequence BCA (Type: OTHER): Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
- Treatment sequence BAC (Type: OTHER): Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
- Treatment sequence CAB (Type: OTHER): Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
- Treatment sequence CBA (Type: OTHER): Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).